Creative Planning grew its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 46.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 157,630 shares of the company's stock after acquiring an additional 49,871 shares during the quarter. Creative Planning's holdings in Takeda Pharmaceutical were worth $2,242,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in TAK. Mondrian Investment Partners LTD increased its holdings in shares of Takeda Pharmaceutical by 47.9% in the 1st quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company's stock valued at $169,119,000 after acquiring an additional 3,912,569 shares during the period. Millennium Management LLC grew its stake in Takeda Pharmaceutical by 87.1% during the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company's stock worth $56,239,000 after buying an additional 2,023,707 shares during the last quarter. Cowen AND Company LLC purchased a new position in Takeda Pharmaceutical during the 2nd quarter worth $6,866,000. Van ECK Associates Corp grew its stake in Takeda Pharmaceutical by 27.3% during the 1st quarter. Van ECK Associates Corp now owns 1,684,760 shares of the company's stock worth $23,401,000 after buying an additional 360,844 shares during the last quarter. Finally, Manning & Napier Advisors LLC purchased a new position in Takeda Pharmaceutical during the 2nd quarter worth $4,098,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.
Takeda Pharmaceutical Stock Up 0.1 %
TAK stock traded up $0.02 on Monday, hitting $13.59. 1,889,391 shares of the company's stock were exchanged, compared to its average volume of 1,857,668. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The firm has a 50 day moving average price of $14.55 and a two-hundred day moving average price of $13.78. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 1.26. The stock has a market cap of $43.24 billion, a P/E ratio of 25.64, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. The firm had revenue of $7.75 billion for the quarter. As a group, equities research analysts expect that Takeda Pharmaceutical Company Limited will post 1.58 EPS for the current fiscal year.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
